After the British-Swedish virus vaccine trial led to ambiguous results, another trial is being considered.
The Astra-Zenika vaccine
Photography:
Reuters
Delay on the road to Astra-Zenika vaccine:
The British-Swedish company announced tonight (Thursday) that it will conduct another trial of the vaccine it has developed for the corona virus, in light of the unequivocal results obtained in the company's previous trial.
The reason for performing the experiment is a mistake made in the previous experiment - then some patients were given only half a dose of vaccine and not a full dose, and despite this, AstraZenica reported a 90% success rate in the experiment.
While the company claims that the experiment proves that the experiment proves that the vaccine is effective even at the low dose, many experts have questioned this.
As a result of the mistake, and the company's announcement of a new trial, which will delay the date of vaccine distribution, the company's share price drops by 0.8%.